Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Monoclonal IGFBPI Primary Antibody for ELISA, WB - ABIN259029
Logan, Ponnampalam, Rahnama, Lobie, Mitchell: The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. in Human reproduction (Oxford, England) 2010
Human Polyclonal IGFBPI Primary Antibody for ELISA, WB - ABIN4321640
Sugita, Morishita, Kano, Furuya, Shiba-Ishii, Noguchi: IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. in Histopathology 2011
Human Polyclonal IGFBPI Primary Antibody for IHC, IHC (p) - ABIN4321641
Bachmann, Burté, Pramana, Conte, Brown, Orimadegun, Ajetunmobi, Afolabi, Akinkunmi, Omokhodion, Akinbami, Shokunbi, Kampf, Pawitan, Uhlén, Sodeinde, Schwenk, Wahlgren, Fernandez-Reyes, Nilsson: Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria. in PLoS pathogens 2014
hypoxia causes PGC (show PGC Antibodies) migration defect by inhibiting IGF signaling through the induction of IGFBP-1
The insulin-like growth factor binding protein 1 (29-31kDa)is similarities to mammalian.
HIF-1 (show HIF1A Antibodies) mediates hypoxia-induced IGFBP-1 gene expression in early development by selectively interacting with the hypoxia response elements and its adjacent HIF-1 (show HIF1A Antibodies) ancillary sequence.
TGE (show TGM3 Antibodies) duplicated IGFBP-1 may provide additional flexibility in fine-tuning insulin (show INS Antibodies)-like growth factor signaling activities under hypoxia and other catabolic conditions.
IGF2, IGF binding protein 1, and matrix metalloproteinases 2 and 9 in implantation-stage endometrium following immunoneutralization of vascular endothelial growth factor (show VEGF Antibodies) in the rhesus monkey.
These data support the hypothesis that down regulation of the insulin (show INS Antibodies)-like growth factor (IGF-I (show IGF1 Antibodies)) signaling links decidual phosphorylated insulin (show INS Antibodies)-like growth factor-binding protein (IGFBP-1) hyperphosphorylation to restricted fetal growth in placental insufficiency.
There was underexpression of the majority of genes after sunitinib treatment. The lower expression levels of IGFBP1, CCL20 (show CCL20 Antibodies), CXCL6 and FGB (show FGB Antibodies) were confirmed by qRT-PCR in all cases. The downregulation of gene expression leads us to search for methylation as a mechanism of action of the tyrosine kinase (show TXK Antibodies) inhibitors
A panel consisting of IGFBP1, KIM1 (show HAVCR1 Antibodies), GCLC (show GCLC Antibodies) and GSTM1 (show GSTM1 Antibodies) genes could be used in combination for early screening of CKDu, whereas these genes in addition with FN1 (show FN1 Antibodies), IGFBP3 (show IGFBP3 Antibodies) and KLK1 (show KLK1 Antibodies) could be used to monitor progression of CKDu. The regulation of these genes has to be studied on larger populations to validate their efficiency for further clinical use.
NR4A modulates the decidualization of hESCs by upregulating prolactin (PRL (show PRL Antibodies)) and insulin-like growth factor binding protein-1 (IGFBP-1) expression and transformation in vitro.
We report interactions between CSNK (show CSN3 Antibodies)-2beta and IGFBP-1 as well as mTOR (show FRAP1 Antibodies) and CSNK (show CSN3 Antibodies)-2beta, providing strong evidence of a mechanistic link between mTOR (show FRAP1 Antibodies) and IGF-I (show IGF1 Antibodies) signaling, two critical regulators of cell growth via CSNK (show CSN3 Antibodies)-2.
IGFBP-1 had a positive linear relation to fracture risk, partly mediated by bone mineral density (BMD (show BEST1 Antibodies)) but not related to IGF-I (show IGF1 Antibodies) or BMD (show BEST1 Antibodies)
We conclude that low BDNF (show BDNF Antibodies) and high LCN2 (show LCN2 Antibodies) and NF-L (show NEFL Antibodies) levels are associated with Multiple Sclerosis (MS) pathogenesis, and high IGFBP1level is a biomarker for female MS only, suggesting different MS progression pathways between the sexes. LCN2 (show LCN2 Antibodies) is a candidate predictor of response to natalizumab treatment, and NF-L (show NEFL Antibodies) is a candidate predictor of clinically isolated syndrome's (CIS (show CISH Antibodies)) conversion into MS.
Results show that IGFBP-1 transcription and FoxO1 (show FOXO1 Antibodies) expression are dysregulated in tamoxifen-resistant cancer cells.
Women with higher IGFBP-1 were more likely to have a low relative muscle mass.
Data show that supplementation with selenium and coenzyme Q10 (show EIF2C2 Antibodies) over four years resulted in increased levels of IGF-1 (show IGF1 Antibodies) and the postprandial IGFBP-1.
the hepatokine IGFBP1 is a critical liver-bone hormonal relay that promotes osteoclastogenesis and bone resorption as well as an essential mediator of FGF21 (show FGF21 Antibodies)-induced bone loss
Data suggest expression of Igfbp1 in liver is regulated by dietary factors; carnosine supplementation down-regulates expression of Igfbp1 in liver of obese/diabetic mice; mechanism involves suppression of Hif1a (hypoxia inducible factor 1 alpha (show HIF1A Antibodies)).
During the two week starvation period, both the levels of plasma IGF-1 (show IGF1 Antibodies) and IGFBP-1 decreased.
These results show that RTEF-1 (show TEAD4 Antibodies)-stimulated IGFBP-1 expression may be central to the mechanism by which RTEF-1 (show TEAD4 Antibodies) attenuates blood glucose levels.
Global deletion of Igfbp1 in a c-Myc (show MYC Antibodies) transgenic model did not accelerate the development of prostate cancer. Global Igfbp1 deletion did result in a significant increase in body weight and body fat mass.
IGFBP-1 functions as a critical hepatic survival factor in the liver by reducing the level of proapoptotic signals
IGFBP-1 may support liver regeneration at least in part via its effect on MAPK/ERK (show MAPK1 Antibodies) and C/EBP beta (show CEBPB Antibodies) activities. These findings are the first demonstration of the involvement of IGFBP-1 in the regulation of in vivo mitogenic signaling pathways.
Induction of IFGBP1 expression by amino acid deprivation of HepG2 hepatoma cells involves both a transcriptional activation and an mRNA stabilization due to its 3'UTR (show UTS2R Antibodies).
high concentrations of circulating IGFBP-1 are sufficient to cause fetal growth restriction in an animal model
the IGFBP-1 gene is a primary target of peroxisome proliferator-activated receptors
Allantoic fluid levels of IGFBP-1 were increased in nuclear transfer pregnancies
IGFBP1 is a common endometrial marker of conceptus elongation in sheep and cattle and most likely regulates conceptus elongation by stimulating migration and attachment of the trophectoderm
Results of fluorescence in situ and radiation hybrid (RH) mapping assigned this gene to porcine chromosome (SSC (show CYP11A1 Antibodies)) 18q24-qter.
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
insulin-like growth factor binding protein 1
, insulin-like growth factor binding protein-1
, IGF-binding protein 1
, alpha-pregnancy-associated endometrial globulin
, amniotic fluid binding protein
, binding protein-25
, binding protein-26
, binding protein-28
, growth hormone independent-binding protein
, insulin-like growth factor-binding protein 1
, placental protein 12
, INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PRECURSOR (IGFBP-1) (IBP-1) (IGF-BINDING PROTEIN 1)